CD274 and ovarian cancer: In addition, trabectedin, a chemopreventative agent approved for sarcoma and in clinical trials for ovarian, prostate, breast and pediatric cancers, increased PD-L1 surface and intracellular protein expression in a murine model of ovarian cancer, which was IFNγ-dependent [83].